MedTrace Logo

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

NCT01017185 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2019-05-23

No results posted yet for this study

Summary

The purpose of this study is to determine whether HF10 is safe and effective in the treatment of head and neck cancer or solid tumors with cutaneous and/or superficial lesions.

Conditions

  • Refractory Head and Neck Cancer
  • Squamous Cell Carcinoma, Skin
  • Carcinoma of the Breast
  • Malignant Melanoma

Interventions

DRUG

HF10

Sponsors & Collaborators

  • Takara Bio Inc.

    lead INDUSTRY

Principal Investigators

  • Robert L Ferris, MD, PhD · Division of Head and Neck Cancer Surgery, University of Pittsburgh Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2014-05-31
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01017185 on ClinicalTrials.gov